Company Filing History:
Years Active: 2025
Title: Yeonjoo Oh: Innovator in Antibody Research
Introduction
Yeonjoo Oh is a prominent inventor based in Seattle, WA (US). He has made significant contributions to the field of biotechnology, particularly in the development of antibodies and chimeric antigen receptors.
Latest Patents
Yeonjoo Oh holds 1 patent for his work on "Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ROR1)." This patent provides receptor tyrosine kinase-like orphan receptor 1 (ROR1)-binding molecules, specifically human antibodies that target ROR1, including antibody fragments. The disclosure also includes recombinant receptors, such as chimeric antigen receptors (CARs) that incorporate these antibodies or fragments, along with polynucleotides encoding the antibodies, antigen-binding fragments, or receptors specific for ROR1. Furthermore, it discusses genetically engineered cells containing these ROR1-binding proteins and receptors, along with related methods and applications in adoptive cell therapy.
Career Highlights
Yeonjoo Oh is currently associated with Juno Therapeutics GmbH, where he continues to advance his research in antibody technology. His work has the potential to impact therapeutic strategies in cancer treatment.
Collaborations
Some of his notable coworkers include Andreia Costa and Rupesh Amin, who contribute to the innovative environment at Juno Therapeutics GmbH.
Conclusion
Yeonjoo Oh's contributions to antibody research and his innovative patent on ROR1-targeting molecules highlight his role as a key figure in biotechnology. His work promises to enhance therapeutic approaches in the medical field.